Pyruvate dehydrogenase complex deficiency and its relationship with epilepsy frequency - An overview

Epilepsy Research

Volumn 116, Issue , 2015, Pages 40-52

  Bhandary, Suman ^a,b   Aguan, Kripamoy ^a  

^a NORTH EASTERN HILL UNIVERSITY   (India)

^b BOSE INSTITUTE   (India)

Author keywords

Antiepileptic drugs; Epilepsy; Ketogenic diet; Metabolic disorder; PDH complex deficiency; PDHA1; X linked

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM CHANNEL; FIBROBLAST GROWTH FACTOR 2; PYRUVATE DEHYDROGENASE COMPLEX; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE DEHYDROGENASE PHOSPHATASE; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE E1ALPHA SUBUNIT;

APOPTOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; E1 ALPHA GENE; ENZYME PHOSPHORYLATION; EPILEPSY; EPILEPTOGENESIS; GABAERGIC TRANSMISSION; HUMAN; KETOGENIC DIET; MEMBRANE STEADY POTENTIAL; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHENOTYPIC VARIATION; PREVALENCE; PRIORITY JOURNAL; PYRUVATE DEHYDROGENASE COMPLEX DEFICIENCY; REVIEW; ANIMAL; COMPLICATION; GENETICS; METABOLISM;

ANIMALS; EPILEPSY; HUMANS; PYRUVATE DEHYDROGENASE (LIPOAMIDE); PYRUVATE DEHYDROGENASE COMPLEX DEFICIENCY DISEASE;

EID: 84940499560     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2015.07.002     Document Type: Review

References (162)

1. Andreassen O.A., Ferrante R.J., Huang H.M., Dedeoglu A., Park L., Ferrante K.L., Kwon J., Borchelt D.R., Ross C.A., Gibson G.E., Beal M.F. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann. Neurol. 2001, 50:112-117.
2. Arjunan P., Nemeria N., Brunskill A. Structure of the pyruvate dehydrogenase multienzyme complex E1 component from Escherichia coli at 1.85Å resolutions. Biochemistry 2002, 41:5213-5221.
3. Baker J.C., Yan X.H., Peng T., Kasten S., Roche T.E. Marked differences between two isoforms of human pyruvate dehydrogenase kinase. J. Biol. Chem. 2000, 275:15773-15781.
4. Barnard J.P., Reynafarje B., Pedersen P.L. Glucose catabolism in African trypanosomes. Evidence that the terminal step is catalyzed by a pyruvate transporter capable of facilitating uptake of toxic analogs. J. Biol. Chem. 1993, 268:3654-3661.
5. Barnerias C., Saudubray J.M., Touati G., De Lonlay P., Dulac O., Ponsot G., et al. Pyruvate dehydrogenase complex deficiency: four neurological phenotypes with differing pathogenesis. Dev. Med. Child Neurol. 2010, 52:e1-e9.
6. Batenburg J.J., Olson M.S. Regulation of pyruvate dehydrogenase by fatty acid in isolated rat liver mitochondria. J. Biol. Chem. 1976, 251:1364-1370.
7. Behal R.H., Buxton D.B., Robertson J.G., Olson M.S. Regulation of the pyruvate dehydrogenase multienzyme complex. Ann. Rev. Nutr. 1993, 13:497-520.
8. A receptor heterogeneity, function, and implications for epilepsy. Neurology 2007, 68:612-614.
9. Benarroch E.E. Potassium channels: brief overview and implications in epilepsy. Neurology 2009, 72:664-669.
10. Bersin R.M., Stacpoole P.W. Dichloroacetate as metabolic therapy for myocardial ischemia and failure. Am. Heart J. 1997, 134:841-855.
11. Bialer M., White H.S. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov. 2010, 9:68-82.
12. Bigger B., Collombet J.M., Coutelle C. Tipping the scales in favour of mitochondrial gene therapy. Gene Ther. 1999, 6:1909-1910.
13. Blass J.P. Hereditary ataxias. Current Neurology 1981, vol. III. John Wiley, New York.
14. Blass J.P., Avigan J., Uhlendorf B.W. A defect in pyruvate decarboxylase deficiency in a child with an intermittent movement disorder. J. Clin. Invest. 1970, 49:423-432.
15. Bough K.J., Rho J.M. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia 2007, 48:43-58.
16. Bowker-Kinley M.M., Davis W.I., Wu P., Harris R.A., Popov K.M. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem. J. 1998, 329:191-196.
17. Bresolin N., Freddo L., Vergani L., Angelini C. Carnitine, carnitine acyltransferases, and rat brain function. Exp. Neurol. 1982, 78:285-292.
18. Broderick T.L., Quinney H.A., Lopaschuk G.D. Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working rat heart. J. Biol. Chem. 1992, 267:3758-3763.
19. Brodie M.J., Covanis A., Gil-Nagel A., Lerche H., Perucca E., Sills G.J., White H.S. Antiepileptic drug therapy: does mechanism of action matter?. Epilepsy Behav. 2011, 21:331-341.
20. Brown R.M., Dahl H.H., Brown G.K. X chromosome localization of the functional gene for the E1 α-subunit of the human pyruvate dehydrogenase complex. Genomics 1989, 4:174-181.
21. Brown G.K., Otero L.J., LeGris M., et al. Pyruvate dehydrogenase deficiency. J. Med. Genet. 1994, 31:875-879.
22. Brown R.M., Head R.A., Boubriak I.I., Leonard J.V., Thomas N.H., Brown G.K. Mutations in the gene for the E1beta subunit: a novel cause of pyruvate dehydrogenase deficiency. Hum. Genet. 2004, 115:123-127.
23. Browning M., Beaudry M., Bennett W.F., Lynch G. Phosphorylation mediated changes in pyruvate dehydrogenase activity influence pyruvate-supported calcium accumulation by brain mitochondria. J. Neurochem. 1981, 36:1932-1940.
24. Butterworth R.F. Neurotransmitter functions in thiamine deficiency encephalopathy. Neurochem. Int. 1982, 4:449-464.
25. Butterworth R.F. Thiamine deficiency and brain disorders. Nutr. Res. Rev. 2003, 16:277-283.
26. Butterworth R.F., Giguere J.F., Besnard A.M. Activities of thiamine-dependent enzymes in two experimental models of thiamine-deficiency encephalopathy. 1. The pyruvate dehydrogenase complex. Neurochem. Res. 1985, 10:1417-1428.
27. Butterworth R.F., Kril J.J., Harper C.G. Thiamine-dependent enzyme changes in the brains of alcoholics: relationship to the Wernicke-Korsakoff syndrome. Alcohol. Clin. Exp. Res. 1993, 17:1084-1088.
28. Cameron J.M., Maj M., Levandovskiy V., Barnett C.P., Blaser S., Mackay N., et al. Pyruvate dehydrogenase phosphatase 1 (PDP1) null mutation produces a lethal infantile phenotype. Hum. Genet. 2009, 125:319-326.
29. Chandrasekhar K., Arjunan P., Sax M., Nemeria N., Jordan F., Furey W. Active-site changes in the pyruvate dehydrogenase multienzyme complex E1 apoenzyme component from Escherichia coli observed at 2.32Å resolutions. Acta Crystallogr. D: Biol. Crystallogr. 2006, 62:1382-1386.
30. Chandy M.J., Ravindra J. Effect of dichloracetate on infarct size in a primate model of focal cerebral ischaemia. Neurol. India 2000, 48:227-230.
31. Chinnery P., Majamaa K., Turnbull D., Thorburn D. Treatment for mitochondrial disorders. Cochrane Database Syst. Rev. 2006, 1:CD004426.
32. Chrzanowska-Lightowlers Z.M., Lightowlers R.N., Turnbull D.M. Gene therapy for mitochondrial DNA defects: is it possible?. Gene Ther. 1995, 2:311-316.
33. Cremer J.E., Lucas H.M. Sodium pentobarbitone and metabolic compartments in rat brain. Brain Res. 1971, 35:619-621.
34. Danial N.N., Hartman A.L., Stafstrom C.E., Thio L.L. How does the ketogenic diet work? Four potential mechanisms. J. Child Neurol. 2013, 28:1027-1033.
35. Davidson B.L., Stein C.S., Heth J.A., Martins I., Kotin R.M., Derksen T.A., Zabner J., Ghodsi A., Chiorini J.A. Recombinant adenoassociated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:3428-3432.
36. De Meirleir L. Defects of pyruvate metabolism and the Kreb's cycle. J. Child Neurol. 2002, 3(Suppl.):S26-S33.
37. De Meirleir L., Lissens W., Vamos E., Liebaers I. Pyruvate dehydrogenase (PDH) deficiency caused by a 21-base pair insertion mutation in the E1α subunit. Hum. Genet. 1992, 88:649-652.
38. De Meirleir L., Van Coster R., Lissens W. Disorders of pyruvate metabolism and the tricarboxylic acid cycle. Inborn Metabolic Diseases: Diagnosis and Treatment 2006, 163-174. Springer Medzin Verlag, Heidelberg. fourth ed. J. Fernandes, J.-M. Saudubray, H. van den Berg (Eds.).
39. DeBoer L.W., Bekx P.A., Han L., Steinke L. Pyruvate enhances recovery of rat hearts after ischemia and reperfusion by preventing free radical generation. Am. J. Physiol. 1993, 265:H1571-H1576.
40. Debray F.G., Lambert M., Chevalier I., et al. Long-term outcome and clinical spectrum of 73 paediatric individuals with mitochondrial diseases. Pediatrics 2007, 119:722-733.
41. Denton R.M., Randle P.J., Martin B.R. Stimulation by calcium ions of pyruvate dehydrogenase phosphate phosphatase. Biochem. J. 1972, 128:161-163.
42. Di Pasquale G., Chiorini J.A. AAV transcytosis through barrier epithelia and endothelium. Mol. Ther. 2006, 13:506-516.
43. Donevan S.D., White H.S., Anderson G.D., Rho J.M. Voltage-dependent block of N-methyl-daspartate receptors by the novel anticonvulsant dibenzylamine, a bioactive constituent of l-(+)-betahydroxybutyrate. Epilepsia 2003, 44:1274-1279.
44. El Sabbagh S., Lebre A.S., Bahi-Buisson N., et al. Epileptic phenotypes in children with respiratory chain disorders. Epilepsia 2010, 51:1225-1235.
45. Evans O.B., Stacpoole P.W. Prolonged hypolactemia and increased total pyruvate dehydrogenase activity by dichloroacetate. Biochem. Pharmacol. 1982, 31:1295-1300.
46. Fouque F., Brivet M., Boutron A., Vequaud C., Marsac C., Zabot M.T., Benelli C. Differential effect of DCA treatment on the pyruvate dehydrogenase complex in patients with severe PDHC deficiency. Pedatr. Res. 2003, 53:793-799.
47. Foust K.D., Nurre E., Montgomery C.L., Hernandez A., Chan C.M., Kaspar B.K. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 2009, 27:59-65.
48. Freeman J.M., Freeman J.B., Kelly M.T. The Ketogenic Diet: A Treatment for Epilepsy 2000, Demos Health, New York, NY. third ed.
49. Frey P.A., Flournoy D.S., Gruys K., Yang Y.S. Intermediates in reductive transacetylation catalyzed by pyruvate dehydrogenase complex. Am. N.Y. Acad. Sci. 1989, 573:21-35.
50. Fryer L.G.D., Orfali K.A., Holness M.J., Saggerson E.D., Sugden M.C. The long term regulation of skeletal muscle pyruvate dehydrogenase kinase by dietary lipid is dependent on fatty acid composition. Eur. J. Biochem. 1995, 229:741-748.
51. Fujii T., Garcia Alvarez M.B., Sheu K.F.R., Franz-Eble P.J., de Vivo D.C. Pyruvate dehydrogenase deficiency: the relation of the E1 α-mutation to the E1 α-subunit deficiency. Pediatr. Neurol. 1996, 14:328-334.
52. Garland P.B., Newsholme E.A., Randle P.J. Regulation of glucose uptake by muscle. 9. Effects of fatty acids and ketone bodies, and of alloxan-diabetes and starvation, on pyruvate metabolism and on lactate/pyruvate and l-glycerol 3-phosphate/dihydroxyacetone phosphate concentration ratios in rat heart and rat diaphragm muscles. Biochem. J. 1964, 91:665-678.
53. Gibson G.E., Jope R., Blass J.P. Decreased synthesis of acetylcholine accompanying impaired oxidation of pyruvic acid in rat brain minces. Biochem. J. 1975, 148:17-23.
54. Gordan J.D., Thompson C.B., Simon M.C. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007, 12:108-113.
55. Hansen L., Brown G.K., Kirby D.M., Dahl H.H.M. Characterization of the mutation of three patients with pyruvate dehydrogenase E1α deficiency. J. Inherit. Metab. Dis. 1991, 14:140-151.
56. Hansford R.G. Studies on the effects of coenzyme A-SH: acetyl coenzyme A, nicotinamide adenine dinucleotide: reduced nicotinamide adenine dinucleotide, and adenosine diphosphate: adenosine triphosphate ratios on the interconversion of active and inactive pyruvate dehydrogenase in isolated rat heart mitochondria. J. Biol. Chem. 1976, 251:5483-5489.
57. Harris M.O., Walsh L.E., Hattab E.M., Golomb M.R. Is it ADEM, POLG, or both?. Arch. Neurol. 2010, 67:493-496.
58. Hartman A.L., Rho J.M. The biochemical basis of dietary therapies for neurological disorders. Dietary Treatment of Epilepsy: Practical Implementation of Ketogenic Therapy 2012, 34-44. Wiley-Blackwell, Oxford, UK. E.G. Neal (Ed.).
59. Head R.A., Brown R.M., Zolkipli Z., Shahdadpuri R., King M.D., Clayton P.T., Brown G.K. Clinical and genetic spectrum of pyruvate dehydrogenase deficiency: dihydrolipoamide acetyltransferase (E2) deficiency. Ann. Neurol. 2005, 58:234-241.
60. Henneberry R.C., Novelli A., Cox J.A., Lysko P.G. Neurotoxicity at the N-methyl-d-aspartate receptor in energy compromised neurons. An hypothesis for cell death in aging and disease. Ann. N.Y. Acad. Sci. 1989, 568:225-233.
61. Hokfelt T. Neuropeptides in perspectives: the last ten years. Neuron 1991, 383:867-879.
62. Huang B., Gudi R., Wu P., Harris R.A., Hamilton J., Popov K.M. Isoenzymes of pyruvate dehydrogenase phosphatase. DNA-derived amino acid sequences, expression, and regulation. J. Biol. Chem. 1998, 273:17680-17688.
63. Iadarola M.J., Gale K. Substantia nigra: site of anticonvulsant activity mediated by gamma-aminobutyric acid. Science 1982, 218:1237-1240.
64. Johnson M.R., Behmoaras J., Bottolo L., et al. Systems-genetics identifies Sestrin 3 as a regulator of a proconvulsant gene network in human epileptic hippocampus. Nat. Commun. 2015, 10.1038/ncomms7031.
65. Joshi C.N., Greenberg C.R., Mhanni A.A., Salman M.S. Ketogenic diet in Alpers-Huttenlocher syndrome. Pediatr. Neurol. 2009, 40:314-316.
66. Jucker B.M., Cline G.W., Barucci N., Shulman G.I. Differential effects of safflower oil versus fish oil feeding on insulin-stimulated glycogen synthesis, glycolysis, and pyruvate dehydrogenase flux in skeletal muscle. Diabetes 1999, 48:134-140.
67. Kaminski R.M., Rogawski M.A., Klitgaard H. The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments. Neurotherapeutics 2014, 11:385-400.
68. Kanzaki T., Hayakawa T., Hamada M., Fukuyosh Y., Koike M. Mammalian alpha-keto acid dehydrogenase complexes. IV. Substrate specificities and kinetic properties of pig heart pyruvate and 2-oxoglutarate dehydrogenase complexes. J. Biol. Chem. 1969, 244:1183-1187.
69. Katayama Y., Welsh F.A. Effect of dichloroacetate on regional energy metabolites and pyruvate dehydrogenase activity during ischemia and reperfusion in gerbil brain. J. Neurochem. 1989, 52:1817-1822.
70. Kerbey A.L., Randle P.J. Role of multi-site phosphorylation in regulation of pig heart pyruvate dehydrogenase phosphatase. FEBS Lett. 1979, 108:485-488.
71. Kerr D.S., Schmotzer C. Variability of human pyruvate dehydrogenase complex deficiency. Thiamine: Catalytic Mechanisms and Role in Normal and Disease States 2004, 471-483. Marcel Dekker Inc., New York. M.S. Patel, F. Jordan (Eds.).
72. Kerr D.S., Zinn A.B. Disorders of pyruvate metabolism and the tricarboxylic acid cycle. Essentials of Pediatric Endocrinology and Metabolism 2009, McGraw-Hill, New York. K. Sarafoglu (Ed.).
73. Kerr D.S., Wexler I.D., Tripatara A., Patel M.S. Defects of the human pyruvate dehydrogenase complex. Alpha Keto Acid Dehydrogenase Complexes 1996, 249-270. Birkhauser Verlag, Basel. M.S. Patel, T. Roche (Eds.).
74. Khurana D.S., Salganicoff L., Melvin J.J., et al. Epilepsy and respiratory chain defects in children with mitochondrial encephalopathies. Neuropediatrics 2008, 39:8-13.
75. Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3:177-185.
76. Klimova T., Chandel N.S. Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ. 2008, 15:660-666.
77. Kohling R. Voltage-gated sodium channels in epilepsy. Epilepsia 2002, 43:1278-1295.
78. Koike M., Reed L.J., Carroll W.R. Alpha-keto acid dehydrogenation complexes. IV. Resolution and reconstitution of the Escherichia coli pyruvate dehydrogenation complex. J. Biol. Chem. 1963, 238:30-39.
79. Korotchkina L.G., Patel M.S. Site specificity of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenase. J. Biol. Chem. 2001, 276:37223-37229.
80. Kunz W.S. The role of mitochondria in epileptogenesis. Curr. Opin. Neurol. 2002, 15:179-184.
81. Kwan P., Sills G.J., Brodie M.J. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol. Ther. 2001, 90:21-34.
82. Lee Y.M., Kang H.C., Lee J.S., et al. Mitochondrial respiratory chain defects: underlying etiology in various epileptic conditions. Epilepsia 2008, 49:685-690.
83. Linn T.C., Pettit F.H., Hucho F., Reed L.J. Alpha-keto acid dehydrogenase complexes. XI. Comparative studies of regulatory properties of the pyruvate dehydrogenase complexes from kidney, heart, and liver mitochondria. Proc. Natl. Acad. Sci. U.S.A. 1969, 64:227-234.
84. Linn T.C., Pettit F.H., Reed L.J. Alpha-keto acid dehydrogenase complexes. X. Regulation of activity of pyruvate dehydrogenase complex from beef kidney mitochondria by phosphorylation and dephosphorylation. Proc. Natl. Acad. Sci. U.S.A. 1969, 62:234-241.
85. Lissens W., De Meirleir L., Seneca S., Liebaers I., Brown G.K., Brown R.M., Ito M., Naito E., Kuroda Y., Kerr D.S., Wexler I.D., Patel M.S., Robinson B.H., Seyda A. Mutations in the X-linked pyruvate dehydrogenase (E1) alpha subunit gene (PDHA1) in patients with a pyruvate dehydrogenase complex deficiency. Hum. Mutat. 2000, 15:209-219.
86. Liu T.C., Kim H., Arizmendi C., Kitano A., Patel M.S. Identification of two missense mutations in a dihydrolipoamide dehydrogenase deficient patient. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:5186-5190.
87. Lu H., Dalgard C.L., Mohyeldin A., McFate T., Tait A.S., Verma A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J. Biol. Chem. 2005, 280:41928-41939.
88. Lutas A., Yellen G. The ketogenic diet: metabolic influences on brain excitability and epilepsy. Trends Neurosci. 2013, 36:32-40.
89. Ma W., Berg J., Yellen G. Ketogenic diet metabolites reduce firing in central neurons by opening K(ATP) channels. J. Neurosci. 2007, 27:3618-3625.
90. Mahbubul Huq A.H.M., Ito M., Naito E., Saijo T., Takeda E., Kuroda Y. Demonstration of an unstable variant of pyruvate dehydrogenase protein (E1) in cultured fibroblasts from a patient with congenital lactic acidosis. Pediatr. Res. 1991, 30:11-14.
91. Maj M.C., MacKay N., Levandovskiy V., Addis J., Baumgartner E.R., Baumgartner M.R., et al. Pyruvate dehydrogenase phosphatase deficiency: identification of the first mutation in two brothers and restoration of activity by protein complementation. J. Clin. Endocrinol. Metab. 2005, 90:4101-4107.
92. Maj M.C., Cameron J.M., Robinson B.H. Pyruvate dehydrogenase phosphatase deficiency: orphan disease or an under-diagnosed condition?. Mol. Cell Endocrinol. 2006, 249:1-9.
93. Mande S.S., Sarfaty S., Allen M.D., Perham R.N., Hol W.G. Protein-protein interactions in the pyruvate dehydrogenase multienzyme complex: dihydrolipoamide dehydrogenase complexed with the binding domain of dihydrolipoamide acetyltransferase. Structure 1996, 4:277-286.
94. Margineantu D.H., Brown R.M., Brown G.K., Marcus A.H., Capaldi R.A. Heterogeneous distribution of pyruvate dehydrogenase in the matrix of mitochondria. Mitochondrion 2002, 1:327-338.
95. Marsac C., François D., Fouque F., Benelli C. Pyruvate dehydrogenase deficiencies. Mitochondrial Diseases, Models and Methods 1999, 174-184. Springer-Verlag, Berlin. P. Lestienne (Ed.).
96. Meldrum B.S., Rogawski M.A. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007, 4:18-61.
97. Morgan D.G., Rottenberg A. Brain pyruvate dehydrogenase: phosphorylation and enzyme activity altered by training exercise. Science 1981, 214:470-471.
98. Morten K.J., Caty M., Matthews P.M. Stabilization of the pyruvate dehydrogenase E1α subunit by dichloroacetate. Neurology 1998, 51:1331-1335.
99. Morten K.J., Beattie P., Brown G.K., Matthews P.M. Dichloroacetate stabilizes the mutant E1 α-subunit in pyruvate dehydrogenase deficiency. Neurology 1999, 53:612-616.
100. Okajima K., Korotchkina L.G., Prasad C., Rupar T., Phillips J.A., Ficicioglu C., et al. Mutations of the E1 beta subunit gene (PDHB) in four families with pyruvate dehydrogenase deficiency. Mol. Genet. Metab. 2008, 93:371-380.
101. Otero L.J., Brown R.M., Brown G.K. Arginine 302 mutations in the pyruvate dehydrogenase E1 α-subunit gene; identification of further patients and in vitro demonstration of pathogenicity. Hum. Mutat. 1998, 12:114-121.
102. Owen R.I.V., Lewin A.P., Peel A., Wang J., Guy J., Hauswirth W.W., Stacpoole P.W., Flotte T.R. Recombinant adeno associated virus vector-based gene transfer for defects in oxidative metabolism. Hum. Gene Ther. 2000, 11:2067-2078.
103. Owen R., Mandel R.J., Ammini C.V., Conlon T.J., Kerr D.S., Stacpoole P.W., Flotte T.R. Gene therapy for pyruvate dehydrogenase E1alpha deficiency using recombinant adeno-associated virus 2 (rAAV2) vectors. Mol. Ther. 2002, 6:394-399.
104. Packman L.C., Green B., Perham R.N. Lipoylation of the E2 components of the 2-oxo acid dehydrogenase multienzyme complexes of Escherichia coli. Biochem. J. 1991, 277:153-158.
105. Paradiso B., Marconi P., Zucchini S., Berto E., Binaschi A., Bozac A., Buzzi A., Mazzuferi M., Magri E., Navarro M.G., Rodi D., Su T., Volpi I., Zanetti L., Marzola A., Manservigi R., Fabene P.F., Simonato M. Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7191-7196.
106. Parikh S., Cohen B.H., Gupta A., Lachhwani D.K., Wyllie E., Kotagal P. Metabolic testing in the pediatric epilepsy unit. Pediatr. Neurol. 2008, 38:191-195.
107. Patel M.S., Korotchkin L.G. Regulation of the pyruvate dehydrogenase complex. Biochem. Soc. Trans. 2006, 34:217-222.
108. Patel M.S., Roche T.E. Molecular biology and biochemistry of pyruvate dehydrogenase complexes. FASEB J. 1990, 4:3224-3233.
109. Patel K.P., O'Brien T.W., Subramony S.H., Shuster J., Stacpoole P.W. The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients. Mol. Genet. Metab. 2011, 105:34-43.
110. Peden C.S., Burger C., Muzyczka N., Mandel R.J. Circulating anti-wild-type adenoassociated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J. Virol. 2004, 78:6344-6359.
111. Perham R.N., Palkman L.C. 2-Oxo acid dehydrogenase multienzyme complexes: domains, dynamics and design. Ann. N.Y. Acad. Sci. 1989, 573:1-20.
112. Pettit F.H., Roche T.E., Reed L.J. Function of calcium ions in pyruvate dehydrogenase phosphatase activity. Biochem. Biophys. Res. Commun. 1972, 49:563-571.
113. Pettit F.H., Pelley J.W., Reed L.J. Regulation of pyruvate dehydrogenase kinase and phosphatase by acetyl-CoA/CoA and NADH/NAD ratios. Biochem. Biophys. Res. Commun. 1975, 65:575-582.
114. Popov K.M., Hawes J.W., Harris R.A. Mitochondrial alpha-ketoacid dehydrogenase kinases: a new family of protein kinases. Adv. Second Messenger Phosphoprotein Res. 1997, 31:105-111.
115. Potashner S.J. Effects of tetrodotoxin, calcium and magnesium on the release of amino acids from slices of guinea pig cerebral cortex. J. Neurochem. 1978, 31:187-195.
116. Pratt M.L., Roche T.E. Mechanism of pyruvate inhibition of kidney pyruvate-dehydrogenase kinase and synergistic inhibition by pyruvate and ADP. J. Biol. Chem. 1979, 254:7191-7196.
117. Randle P.J. Mitochondrial 2-oxoacid dehydrogenase complexes of animal tissues. Philos. Trans. R. Soc. Lond. B 1983, 302:47-57.
118. Randle P.J. Fuel selection in animals. Biochem. Soc. Trans. 1986, 14:799-806.
119. Randle P.J., Garland P.B., Hales C.N., Newsholme E.A. The glucose-fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 13:786-789.
120. Randle P.J., Kerbey A.L., Espinal J. Mechanisms decreasing glucose oxidation in diabetes and starvation: role of lipid fuels and hormones. Diabetes Metab. Rev. 1988, 4:623-638.
121. Richichi C., Lin E.D., Stefanin D., Colella D., Ravizza T., Grignaschi G., Veglianese P., Sperk G., During M.J., Vezzani A. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J. Neurosci. 2004, 24:3051-3059.
122. Rigobello M.P., Bindoli A. Effect of pyruvate on rat heart thiol status during ischemia and hypoxia followed by reperfusion. Mol. Cell. Biochem. 1993, 122:93-100.
123. Robinson B.H. Lactacidemia: biochemical, clinical and genetic considerations. Adv. Hum. Genet. 1989, 18:159-179.
124. Robinson B.H. Lactic acidemia (disorders of pyruvate carboxylase, pyruvate dehydrogenase). The Metabolic and Molecular Bases of Inherited Disease 1995, 1479-1499. McGraw-Hill, New York. seventh ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
125. Robinson B.H. Lactic acidemia (disorders of pyruvate carboxylase, pyruvate dehydrogenase). Metabolic and Molecular Bases of Inherited Disease 2000, 1479-1499. McGraw-Hill, New York. eighth ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
126. Robinson B.H. Lactic acidemia: disorders of pyruvate carboxylase and pyruvate dehydrogenase. The Metabolic and Molecular Basis of Inherited Disease 2001, vol. II:2275-2295. McGraw-Hill, New York.
127. Robinson B.H., Sherwood W.G. Lactic academia. J. Inherit. Metab. Dis. 1984, 7:69-73.
128. Robinson B.H., MacKay N., Petrova-Benedict R., Ozalp I., Coskun T., Stacpoole P.W. Defects in the E2 lipoyl transacetylase and the X-lipoyl containing component of the pyruvate dehydrogenase complex in patients with lactic academia. J. Clin. Invest. 1990, 85:1821-1824.
129. Roche T.E., Hiromasa Y. Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer. Cell. Mol. Life Sci. 2007, 64:830-849.
130. Roche T.E., Baker J.C., Yan Y.H., Hiromasa Y., Gong X.M., Peng T., Kasten S.A. Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms. Prog. Nucleic Acid Res. Mol. Biol. 2001, 70:33-75.
131. Sada N., Lee S., Katsu T., Otsuki T., Inoue T. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science 2015, 347:1362-1367.
132. Scaglia F., Towbin J.A., Craigen W.J., Belmont J.W., Smith E.O., Neish S.R., Ware S.M., Hunter J.V., Fernbach S.D., Vladutiu G.D., Wong L.J., Vogel H. Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics 2004, 114:925-931.
133. Schwartzkroin P.A. Mechanisms underlying the anti-epileptic efficacy of the ketogenic diet. Epilepsy Res. 1999, 37:171-180.
134. Semenza G.L. Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning. Biochim. Biophys. Acta 2011, 1813:1263-1268.
135. Seo J.H., Lee Y.M., Lee J.S., Kang H.C., Kim H.D. Efficacy and tolerability of the ketogenic diet according to lipid: nonlipid ratios - comparison of 3:1 with 4:1 diet. Epilepsia 2007, 48:801-805.
136. Sheu K.F., Kim Y.T., Blass J.P., Weksler M.E. An immunochemical study of the pyruvate dehydrogenase deficit in Alzheimer's disease brain. Ann. Neurol. 1985, 17:44-449.
137. Simonato M. Gene therapy for epilepsy. Epilepsy Behav. 2014, 38:125-130.
138. Simpson N.E., Han Z., Berendzen K.M., Sweeney C.A., Oca-Cossio J.A., Constantinidis I., Stacpoole P.W. Magnetic resonance spectroscopic investigation of mitochondrial fuel metabolism and energetics in cultured human fibroblasts: effects of pyruvate dehydrogenase complex deficiency and dichloroacetate. Mol. Genet. Metab. 2006, 89:97-105.
139. Smolle M., Prior A.E., Brown A.E., Cooper A., Byron O., Lindsay J.G. A new level of architectural complexity in the human pyruvate dehydrogenase complex. J. Biol. Chem. 2006, 281:19772-19780.
140. Sorbi S., Blass J.P. Abnormal activation of pyruvate dehydrogenase in Leigh disease fibroblasts. Neurology 1982, 32:555-558.
141. Stacpoole P.W. Pharmacology of DCA. Metabolism 1989, 38:1124-1144.
142. Stacpoole P.W. Lactic acidosis and other mitochondrial disorders. Metabolism 1997, 46:306-321.
143. Stacpoole P.W., Gilbert L.R. Pyruvate dehydrogenase complex deficiency. Clinical Cases in Medical Biochemistry 2006, 77-88. Oxford University Press, New York. R.H. Glew, M.D. Rosenthal (Eds.).
144. Stacpoole P.W., Barnes C.L., Hurbanis M.D., Cannon S.L., Kerr D.S. Treatment of congenital lactic acidosis with dichloroacetate. Arch. Dis. Child. 1997, 77:535-541.
145. Sugden P.H., Simister N.E. Role of multisite phosphorylation in the regulation of ox kidney pyruvate dehydrogenase complex. FEBS Lett. 1980, 111:299-302.
146. Sugden P.H., Hutson N.J., Kerbey A.L., Randle P.J. Phosphorylation of additional sites on pyruvate dehydrogenase inhibits its re-activation by pyruvate dehydrogenase phosphate phosphatase. Biochem. J. 1978, 169:433-435.
147. Sugden P.H., Kerbey A.L., Randle P.J., Waller C.A., Reid K.B. Amino acid sequences around the sites of phosphorylation in the pig heart pyruvate dehydrogenase complex. Biochem. J. 1979, 181:419-426.
148. Teague W.M., Pettit F.H., Yearnan S.H., Reed L.J. Function of phosphorylation sites on pyruvate dehydrogenase. Biochem. Biophys. Res. Commun. 1979, 87:244-252.
149. Thio L.L., Wong M., Yamada K.A. Ketone bodies do not directly alter excitatory or inhibitory hippocampal synaptic transmission. Neurology 2000, 54:325-331.
150. Toshima K., Kuroda Y., Hashimoto T. Enzymologic studies and therapy of Leigh disease associated with pyruvate decarboxylase deficiency. Pediatr. Res. 1982, 16:430-435.
151. Urbanska E.M., Blaszczak P., Saran T., Kleinrok Z., Turski W.A. Mitochondrial toxin 3-nitropropionic acid evokes seizures in mice. Eur. J. Pharmacol. 1998, 359:55-58.
152. Vary T.C. Increased pyruvate dehydrogenase kinase activity in response to sepsis. Am. J. Physiol. 1991, 260:669-674.
153. Vezzani A., French J., Bartfai T., Baram T.Z. The role of inflammation in epilepsy. Nat. Rev. Neurol. 2011, 7:31-40.
154. Whitehouse S., Cooper R.H., Randle P.J. Mechanism of activation of pyruvate dehydrogenase by dichloroacetate. Biochem. J. 1974, 41:761-774.
155. Wieland O.H. The mammalian pyruvate dehydrogenase complex: structure and regulation. Rev. Physiol. Biochem. Pharmacol. 1983, 96:123-170.
156. Xi L., Brown K., Woodworth J., Shim K., Johnson B., Odle J. Maternal dietary l-carnitine supplementation influences fetal carnitine status and stimulates carnitine palmitoyltransferase and pyruvate dehydrogenase complex activities in swine. J. Nutr. 2008, 138:2356-2362.
157. Yamamoto H., Tang H.W. Preventive effect of melatonin against cyanide-induced seizures and lipid peroxidation in mice. Neurosci. Lett. 1996, 207:89-92.
158. Yeaman S.J. The 2-oxo acid dehydrogenase complexes: recent advances. Biochem. J. 1989, 257:625-632.
159. Yu X., Hiromasa Y., Tsen H., Stoops J.K., Roche T.E., Zhou Z.H. Structures of the human pyruvate dehydrogenase complex cores: a highly conserved catalytic center with flexible N-terminal domains. Structure 2008, 16:104-114.
160. Zhou Z.H., McCarthy D.B., O'Connor C.M., Reed L.J., Stoops J.K. The remarkable structural and functional organization of the eukaryotic pyruvate dehydrogenase complexes. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:14802-14807.
161. Zini S., Roisin M.P., Langel U., Bartfai T., Ben-Ari Y. Galanin reduces release of endogenous excitatory amino acids in the rat hippocampus. Eur. J. Pharmacol. 1993, 245:1-7.
162. Zullo S.J. Gene therapy of mitochondrial DNA mutations: a brief, biased history of allotopic expression in mammalian cells. Semin. Neurol. 2001, 21:327-336.